Breaking Finance News

Zacks Investment Research disclosed Galapagos NV (ADR) (NASDAQ:GLPG), upping its target price to $74.00 today

Boasting a price of $65.64, Galapagos NV (ADR) (NASDAQ:GLPG) traded 0.83% higher on the day. With the last stock price close up 22.68% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Galapagos NV (ADR) has recorded a 50-day average of $60.30 and a two hundred day average of $53.51. Volume of trade was up over the average, with 95,051 shares of GLPG changing hands over the typical 80,311

Galapagos NV (ADR) (NASDAQ:GLPG) had its price target upped to $74.00 by Zacks Investment Research in an issued report announced 10/10/2016. The updated stock price target implies a potential upside of 0.13% based on the company's most recent stock price close.

Performance Chart

Galapagos NV (ADR) (NASDAQ:GLPG)

With a total market value of $0, Galapagos NV (ADR) has with a one year low of $37.03 and a one year high of $73.37 .

A total of 1 equity analyst has released a ratings update on GLPG. zero equity analysts rating the company a strong buy, two equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $92.78.

Brief Synopsis About Galapagos NV (ADR) (NASDAQ:GLPG)

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *